Opioid Studies In Children Still Facing Design Challenges
Executive Summary
FDA cites Purdue and Mallinckrodt over required assessments for Dilaudid and Xartemis XR, respectively; Merck also draws letter for failing to timely submit a PREA study labeling change for the antibiotic Cubicin.
You may also be interested in...
Opioid Development Strategies In Pediatrics To Get FDA Advisory Panel Help
While FDA has long required pediatric analgesic studies, very few sponsors have managed to complete them, mainly due to enrollment challenges; advisory committees will offer recommendations on other designs that may bring a more successful result.
Pediatric Study Compliance Could Face Scrutiny In PDUFA Renewal
FDA says compliance is on par with other postmarketing requirements, but jury is still out on whether public posting of noncompliance letters has been effective tool to ensure timely trial completion.
Pediatric Study Compliance Could Face Scrutiny In PDUFA Renewal
FDA says compliance is on par with other postmarketing requirements, but jury is still out on whether public posting of noncompliance letters has been effective tool to ensure timely trial completion.